Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824170 | 1.00 | CAPN1 (0.44) | CAPN1ALDH1A1MAPTEPHX2FAAH | |
| SCHEMBL21711009 | 0.89 | ALDH1A1 (0.44) | ALDH1A1MAPTEPHX2FAAHCNR1 | |
| SCHEMBL1823120 | 0.89 | ALDH1A1 (0.44) | ALDH1A1MAPTEPHX2FAAHCNR1 | |
| SCHEMBL1819306 | 0.89 | ALDH1A1 (0.44) | ALDH1A1MAPTEPHX2FAAHCNR1 | |
| SCHEMBL5957041 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPTEPHX2FAAHCNR1 | |
| SCHEMBL12273911 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MAPTEPHX2FAAHCNR1 | |
| SCHEMBL5941168 | 0.80 | TSHR (0.49) | ALDH1A1MAPTLMNA | |
| SCHEMBL5941153 | 0.80 | ALDH1A1 (0.46) | ALDH1A1MAPTEPHX2FAAHCNR1 | |
| SCHEMBL22494092 | 0.79 | FAAH (0.61) | ALDH1A1MAPTEPHX2FAAHCNR1 | |
| SCHEMBL22494093 | 0.79 | FAAH (0.61) | ALDH1A1MAPTEPHX2FAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20180325923-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| EP-2813486-B1 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2315740-B1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2813486-B1 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2315740-B1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-8173831-B2 | Fatty acid acetylated salicylates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2315740-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | CATABASIS PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | CATABASIS PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | CATABASIS PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010006085-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010006085-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046738-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | CAPN1 1901/4885ALDH1A1 285/4885MAPT 2633/4885 |
| US-20180325923-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | CAPN1 1901/4885ALDH1A1 285/4885MAPT 2633/4885 |
| US-20170246193-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | CAPN1 1901/4885ALDH1A1 285/4885MAPT 2633/4885 |
| US-20100041748-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | CAPN1 1901/4885ALDH1A1 285/4885MAPT 2633/4885 |
| US-20210169905-A1 | FATTY ACID ACETYLATED SALICYLATES AND THEIR USES | FASN, ACACA, FABP4 | CAPN1 1901/4885ALDH1A1 285/4885MAPT 2633/4885 |
| US-20100184730-A1 | Fatty Acid Acylated Salicylates and Their Uses | FADS1, FASN, ALOX5 | CAPN1 2576/4885ALDH1A1 230/4885MAPT 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.